168 related articles for article (PubMed ID: 2242381)
1. A model for computer simulation of P-glycoprotein and transmembrane delta pH-mediated anthracycline transport in multidrug-resistant tumor cells.
Demant EJ; Sehested M; Jensen PB
Biochim Biophys Acta; 1990 Nov; 1055(2):117-25. PubMed ID: 2242381
[TBL] [Abstract][Full Text] [Related]
2. Daunorubicin and vincristine binding to plasma membrane vesicles from daunorubicin-resistant and wild type Ehrlich ascites tumor cells.
Sehested M; Bindslev N; Demant EJ; Skovsgaard T; Jensen PB
Biochem Pharmacol; 1989 Sep; 38(18):3017-27. PubMed ID: 2571333
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein.
Nielsen D; Maare C; Skovsgaard T
Biochem Pharmacol; 1994 Jun; 47(12):2125-35. PubMed ID: 7913318
[TBL] [Abstract][Full Text] [Related]
4. Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.
Friche E; Demant EJ; Sehested M; Nissen NI
Br J Cancer; 1993 Feb; 67(2):226-31. PubMed ID: 8094288
[TBL] [Abstract][Full Text] [Related]
5. The carboxylic ionophore monensin inhibits active drug efflux and modulates in vitro resistance in daunorubicin resistant Ehrlich ascites tumor cells.
Sehested M; Skovsgaard T; Roed H
Biochem Pharmacol; 1988 Sep; 37(17):3305-10. PubMed ID: 3401258
[TBL] [Abstract][Full Text] [Related]
6. Characterization of tumor cell resistance to 4'-deoxy-4'-iododoxorubicin developed in Ehrlich ascites cells in vivo.
Friche E; Danks MK; Beck WT
Cancer Res; 1992 Oct; 52(20):5701-6. PubMed ID: 1356619
[TBL] [Abstract][Full Text] [Related]
7. Cytosolic free Ca2+ in daunorubicin and vincristine resistant Ehrlich ascites tumor cells. Drug accumulation is independent of intracellular Ca2+ changes.
Bouchelouche P; Friche E; Sehested M; Jensen PB; Skovsgaard T
Biochem Pharmacol; 1991 Jan; 41(2):243-53. PubMed ID: 1899193
[TBL] [Abstract][Full Text] [Related]
8. Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells.
Sehested M; Skovsgaard T; Jensen PB; Demant EJ; Friche E; Bindslev N
Br J Cancer; 1990 Jul; 62(1):37-41. PubMed ID: 1975202
[TBL] [Abstract][Full Text] [Related]
9. Relationship of VP-16 to the classical multidrug resistance phenotype.
Sehested M; Friche E; Jensen PB; Demant EJ
Cancer Res; 1992 May; 52(10):2874-9. PubMed ID: 1581902
[TBL] [Abstract][Full Text] [Related]
10. Expression of P-glycoprotein and multidrug resistance associated protein in Ehrlich ascites tumor cells after fractionated irradiation.
Nielsen D; Maare C; Eriksen J; Litman T; Skovsgaard T
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1050-7. PubMed ID: 11704330
[TBL] [Abstract][Full Text] [Related]
11. Influence of chemosensitizers on resistance mechanisms in daunorubicin-resistant Ehrlich ascites tumour cells.
Nielsen D; Eriksen J; Maare C; Friche E; Skovsgaard T
Cancer Chemother Pharmacol; 2002 Jun; 49(6):453-60. PubMed ID: 12107549
[TBL] [Abstract][Full Text] [Related]
12. The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.
Friche E; Jensen PB; Sehested M; Demant EJ; Nissen NN
Cancer Commun; 1990; 2(9):297-303. PubMed ID: 1976341
[TBL] [Abstract][Full Text] [Related]
13. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells.
Friche E; Danks MK; Schmidt CA; Beck WT
Cancer Res; 1991 Aug; 51(16):4213-8. PubMed ID: 1678312
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide.
Nielsen D; Maare C; Eriksen J; Litman T; Friche E; Skovsgaard T
Biochem Pharmacol; 2000 Aug; 60(3):353-61. PubMed ID: 10856430
[TBL] [Abstract][Full Text] [Related]
15. Influx of daunorubicin in multidrug resistant Ehrlich ascites tumour cells: correlation to expression of P-glycoprotein and efflux. Influence of verapamil.
Nielsen D; Maare C; Skovsgaard T
Biochem Pharmacol; 1995 Aug; 50(4):443-50. PubMed ID: 7646548
[TBL] [Abstract][Full Text] [Related]
16. Multidrug resistance-modifying components in human plasma with potential clinical significance.
Mülder HS; Pinedo HM; Timmer AT; Rao BR; Lankelma J
J Exp Ther Oncol; 1996 Jan; 1(1):13-22. PubMed ID: 9414384
[TBL] [Abstract][Full Text] [Related]
17. In vitro circumvention of anthracycline--resistance in Ehrlich ascites tumour by anthracycline analogues.
Friche E; Jensen PB; Roed H; Skovsgaard T; Nissen NI
Biochem Pharmacol; 1990 Jun; 39(11):1721-6. PubMed ID: 2344368
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein preferentially effluxes anthracyclines containing free basic versus charged amine.
Frézard F; Pereira-Maia E; Quidu P; Priebe W; Garnier-Suillerot A
Eur J Biochem; 2001 Mar; 268(6):1561-7. PubMed ID: 11248673
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of non-P-glycoprotein multidrug-resistant Ehrlich ascites tumour cells selected for resistance to mitoxantrone.
Nielsen D; Eriksen J; Maare C; Litman T; Kjaersgaard E; Plesner T; Friche E; Skovsgaard T
Biochem Pharmacol; 2000 Aug; 60(3):363-70. PubMed ID: 10856431
[TBL] [Abstract][Full Text] [Related]
20. Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor.
Friche E; Jensen PB; Nissen NI
Cancer Chemother Pharmacol; 1992; 30(3):235-7. PubMed ID: 1628375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
